# Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects

> **NCT00979251** · PHASE2 · COMPLETED · sponsor: **Adamas Pharmaceuticals, Inc.** · enrollment: 2 (actual)

## Conditions studied

- Influenza

## Interventions

- **DRUG:** Oseltamivir Phosphate
- **DRUG:** ADS-8902

## Key facts

- **NCT ID:** NCT00979251
- **Lead sponsor:** Adamas Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2010-05
- **Final completion:** 2011-08
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2014-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00979251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00979251, "Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00979251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*